0001867096-24-000107.txt : 20240605 0001867096-24-000107.hdr.sgml : 20240605 20240605161908 ACCESSION NUMBER: 0001867096-24-000107 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240605 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BORMANN-KENNEDY BARBARA-JEAN ANNE CENTRAL INDEX KEY: 0001635065 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40880 FILM NUMBER: 241022245 MAIL ADDRESS: STREET 1: 1188 BROADWAY, SUITE 306 CITY: SOMERVILLE STATE: MA ZIP: 02144 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc. CENTRAL INDEX KEY: 0001867096 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 871082097 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 BUSINESS PHONE: 844-445-5704 MAIL ADDRESS: STREET 1: 1375 WEST FULTON STREET, SUITE 1300 CITY: CHICAGO STATE: IL ZIP: 60607 4 1 wk-form4_1717618739.xml FORM 4 X0508 4 2024-06-05 0 0001867096 Xeris Biopharma Holdings, Inc. XERS 0001635065 BORMANN-KENNEDY BARBARA-JEAN ANNE C/O XERIS BIOPHARMA HOLDINGS, INC. 1375 WEST FULTON STREET, SUITE 1300 CHICAGO IL 60607 1 0 0 0 0 Common Stock 2024-06-05 4 A 0 50000 0 A 107500 D These shares were acquired pursuant to a restricted stock unit award under the Company's 2018 Stock Option and Incentive Plan. Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in full upon the earlier to occur of June 5, 2025 or the date of the Company's next annual meeting of stockholders. /s/ Beth Hecht, as Attorney-in-Fact 2024-06-05